This week’s episode will be focusing on treatment options for localized breast cancer with 2025 updates. We will go over important details on indications for adjuvant radiation, as well as therapies based on the ER/PR/HER-2 receptor status.
Sep 28
ctDNA & MRD: Current Applications, Limitations & What’s Next
This week’s episode we are very excited to welcome back our special guest Dr. Hatim Husain, MD, a medical oncologist and physician-scientist at UC San Diego Moores Cancer Center, whose clinical and research expertise focuses on lung cancer and precision oncology. We further cover ... Show More
19m 12s
Sep 21
ctDNA, Liquid Biopsies, Methylation, NGS: What Does It All Mean?
This week’s episode we are very excited to welcome a special guest Dr. Hatim Husain, MD, a medical oncologist and physician-scientist at UC San Diego Moores Cancer Center, whose clinical and research expertise focuses on lung cancer and precision oncology. We cover the topic of l ... Show More
27 m
Mar 2024
Endocrine and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer – Capivasertib-Fulvestrant: Rapid Guideline Update
Dr. Angela DeMichele, Dr. Lynn Henry, and Dr. Harold Burstein present the latest breast cancer rapid recommendation update impacting two ASCO guidelines. This update focuses on the new option, capivasertib plus fulvestrant, for patients with hormone receptor-positive, HER2-negati ... Show More
14m 9s
Nov 2023
Hereditary Breast Cancer, Genetic Testing, and Therapeutic Implications
Join Drs Kevin Kalinsky and Jennifer Litton as they discuss hereditary breast cancer, genetic testing, and therapeutic implications. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991258). The topics and discussions ... Show More
19m 26s
Feb 2025
143. San Antonio Breast Cancer Symposium 2024 - Part 2
<p>Our second SABCS (San Antonio Breast Cancer Symposium) episode covers everything (else) you need to know from 2024. </p><br><p>In this episode, we dive into the role of trastuzumab deruxtecan in HR +ve, HER2 low cancers, perioperative atezolizumab in tnbc, the use of a novel A ... Show More
20m 57s
Dec 2024
141. Back to Basics - The role of endocrine therapy in Breast Cancer
<p>Before immunotherapy, targeted chemotherapy (ADCs) and precision oncology, there was endocrine therapy, the forefather (or mother) of effective treatment to reduce breast cancer recurrence as well as delay disease progression. This episode dives into a past of phenomenal impro ... Show More
24m 4s